Search results for "autoantibody"

showing 10 items of 249 documents

Emerging Therapies in Immune Thrombocytopenia

2021

Immune thrombocytopenia (ITP) is a rare autoimmune disorder caused by peripheral platelet destruction and inappropriate bone marrow production. The management of ITP is based on the utilization of steroids, intravenous immunoglobulins, rituximab, thrombopoietin receptor agonists (TPO-RAs), immunosuppressants and splenectomy. Recent advances in the understanding of its pathogenesis have opened new fields of therapeutic interventions. The phagocytosis of platelets by splenic macrophages could be inhibited by spleen tyrosine kinase (Syk) or Bruton tyrosine kinase (BTK) inhibitors. The clearance of antiplatelet antibodies could be accelerated by blocking the neonatal Fc receptor (FcRn), while n…

TPO-RAlcsh:MedicineSykReview03 medical and health sciencesClassical complement pathway0302 clinical medicinehemic and lymphatic diseasesMedicineBruton's tyrosine kinasePlateletB celldesialylationbiologybusiness.industrylcsh:RBTK inhibitorAutoantibodyGeneral MedicineFcRnmedicine.anatomical_structureimmune thrombocytopeniaSyk inhibitor030220 oncology & carcinogenesisImmunologybiology.proteinRituximabAntibodybusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report

2021

AbstractImmune thrombotic thrombocytopenic purpura (iTTP) is a rare autoimmune disorder characterized by severely reduced activity of the von Willebrand factor (VWF)-cleaving protease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) due to autoantibodies. This leads to the development of pathogenic multimers of VWF, causing a thrombotic microangiopathy with decreased number of platelets, hemolysis, and life-threatening tissue ischemia of mostly brain, heart, and kidneys. Standard treatment of iTTP involves daily plasma exchange to remove ultra large multimers of VWF, inhibitors, substituting ADAMTS13, and the accompaniment of an immunosuppressive …

Thrombotic microangiopathybiologybusiness.industryThrombotic thrombocytopenic purpuraAutoantibodyHematology030204 cardiovascular system & hematologymedicine.diseaseADAMTS1303 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseases030220 oncology & carcinogenesisImmunologybiology.proteinmedicineRituximabPlateletCaplacizumabbusinessmedicine.drugHämostaseologie
researchProduct

Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ionization-time of flight mass spectrometry

2003

Normal sera contain a large number of naturally occurring autoantibodies which can mask important disease-associated ones. Western blotting has evolved as the most important tool to demonstrate autoantibodies in autoimmune diseases, because of its ability to simultaneous screening for a wide spectrum of different antigens. In previous studies we have shown the diagnostic potential of the analysis of autoantibodies in autoimmune diseases by means of multivariate statistics and artificial neural networks. However, the Western blotting procedure remains very time-consuming and is also limited in sensitivity. Therefore, we used an on-chip approach for the analysis of autoantibodies. This Protei…

Time FactorsChromatographymedicine.diagnostic_testMolecular massmedicine.drug_classChemistryBlotting WesternProtein Array AnalysisAutoantibodyMass spectrometryMonoclonal antibodySensitivity and SpecificityBiochemistryMass SpectrometrySurface-enhanced laser desorption/ionizationMolecular WeightBlotWestern blotSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationmedicineHumansTime-of-flight mass spectrometryMolecular BiologyAutoantibodiesPROTEOMICS
researchProduct

Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

2021

International audience; Background Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by anti-ADAMTS13 autoantibodies inducing a severe deficiency of ADAMTS13. Epitope mapping studies on samples obtained during acute iTTP episodes have shown that the iTTP immune response is polyclonal, with almost all patients having autoantibodies targeting the spacer domain of ADAMTS13.Objectives To identify the immunogenic hotspots in the spacer domain of ADAMTS13.Patients/methods A library of 11 full-length ADAMTS13 spacer hybrids was created in which amino acid regions of the spacer domain of ADAMTS13 were exchanged by the corresponding region of the spacer domain of ADAMTS1. Next, th…

autoantibodiesADAMTS13 Protein030204 cardiovascular system & hematologyEpitope03 medical and health sciencesEpitopes0302 clinical medicineVon Willebrand factorimmunophenotypinghemic and lymphatic diseasesHumansthrombotic thrombocytopenic purpurachemistry.chemical_classificationbiologyPurpura Thrombotic ThrombocytopenicAutoantibodyHematologyMolecular biologyADAMTS13ADAMTS133. Good healthAmino acidepitope mappingEpitope mappingchemistryPolyclonal antibodiesImmunoglobulin Gbiology.proteinDNA IntergenicAntibody[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Synthesis of organometallic glycopeptides and electrochemical studies to detect autoantibodies in multiple sclerosis patients' sera

2009

Feliciana Real-Fernandez, Amelie Chamois-Colson, Jerome Bayardon, Francesca Nuti, Elisa Peroni, Maria R. Moncelli, Rita Meunier-Prest, Sylvain Juge and Anna Maria Papini Laboratory of Peptide & Protein Chemistry & Biology, Polo Scientifico, University of Florence, I-50019 Sesto Fiorentino (FI), Italy; Laboratoire de Synthese et d’Electrosynthese Organometalliques (LSEO), Universite de Bourgogne, 21068, Dijon, France

autoantibodiesPeptideProtein chemistrymultiple sclerosis03 medical and health sciences0302 clinical medicinebloodmedicineProtein antigen030304 developmental biologychemistry.chemical_classification0303 health sciencesMultiple sclerosisAutoantibodyglycopeptides[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.diseaseMolecular biologyGlycopeptide3. Good healthchemistryelectrochemistryImmunology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieenzyme-linked immunosorbent assay030217 neurology & neurosurgery
researchProduct

Clinical relevance of antiphospholipid antibodies in primary biliary cirrhosis.

2005

Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies (AMAs), but also with reactivities to other autoantigens. Recent studies showed that antibodies to phospholipids (APAs) represent an important group of autoantibodies identified in patients with PBC. In this study different types of APAs were identified in the sera of patients with PBC and autoimmune hepatitis (AIH) and control subjects. Sera from patients with PBC and AIH were tested for the presence of antibodies directed against cardiolipin (CL), phosphatidylserine (PS), and to beta(2)-glycoprotein I (beta(2)-GPI). Furthermore, an in-house test for antithrombop…

biologyAnti-nuclear antibodybusiness.industryLiver Cirrhosis BiliaryGeneral NeuroscienceAutoantibodyAutoimmune hepatitismedicine.diseasedigestive system diseasesGeneral Biochemistry Genetics and Molecular BiologyHepatitis AutoimmunePrimary biliary cirrhosisHistory and Philosophy of ScienceImmunoglobulin MImmunoglobulin MImmunologybiology.proteinAntibodies AntiphospholipidMedicineAlkaline phosphataseHumansClinical significanceAntibodyskin and connective tissue diseasesbusinessAnnals of the New York Academy of Sciences
researchProduct

Soluble liver antigen (SLA) antibody detection by ELISA and multiplexing technologies

2002

Abstract Objective: Develop and evaluate assays for the detection of antibodies to soluble liver antigen (SLA). SLA, also known as liver/pancreas antibody, was found to be 100% specific for autoimmune hepatitis (AIH) in a recent study of 2000 sera collected from individuals with various disease conditions and healthy individuals (Wies et al., Lancet 2000; 355:1510). Although SLA antibodies occur in only about 30% of patients with autoimmune hepatitis, they are found in some individuals with AIH who are negative for other autoantibodies. Methods: Specimens from patients with autoimmune hepatitis, non-autoimmune liver disease, various autoimmune conditions, as well as specimens from healthy i…

biologymedicine.diagnostic_testbusiness.industryfungiImmunologyAutoantibodyAutoimmune hepatitismedicine.diseaseMicrobiologylaw.inventionLiver diseaseInfectious DiseasesWestern blotlawImmunologyRecombinant DNAbiology.proteinImmunology and AllergyMedicineMultiplexAntibodybusinessViral hepatitisClinical and Applied Immunology Reviews
researchProduct

P68 A diet rich in wheat alpha-amylase/trypsin inhibitors (ATIs) enhances disease progression in the MRL-Fas(lpr) mouse model of systemic lupus eryth…

2020

Background Wheat alpha-amylase/trypsin inhibitors (ATIs) are the second most prevalent proteins in wheat (3–4% vs 80–90% for gluten) and potent activators of the innate immune system via the toll like receptor 4 (TLR4)-MD2-CD14 complex in cells of the mononuclear phagocyte system (Junker Y et al, J Exp Med 2012), triggering several autoimmune/inflammatory diseases. In contrast, pure gluten that is de-enriched of ATIs shows no stimulatory activity. MRL-Fas(lpr) mice develop progressive and spontaneous glomerular, tubulointerstitial and perivascular kidney disease, arthritis, lymphadenopathy, splenomegaly and circulating autoantibodies in a syndrome that resembles systemic lupus erythematosus…

business.industryAutoantibodyArthritisSpleenInflammationMononuclear phagocyte systemurologic and male genital diseasesmedicine.diseaseProinflammatory cytokinemedicine.anatomical_structureimmune system diseasesImmunologymedicineTumor necrosis factor alphaHemoglobinuriamedicine.symptomskin and connective tissue diseasesbusinessPoster presentations
researchProduct

Does autoimmunity play a part in the pathogenesis of glaucoma?

2013

Glaucoma is a chronic neurodegenerative disease and one of the leading causes of blindness. Several risk factors have been described, e.g. an elevated intraocular pressure (IOP), oxidative stress or mitochondrial dysfunction. Additionally, alterations in serum antibody profiles of glaucoma patients, upregulation (e.g. anti-HSP60, anti-MBP) and downregulation (e.g. anti-14-3-3), have been described, but it still remains elusive if the autoantibodies seen in glaucoma are an epiphenomenon or causative. However, it is known that elicited autoimmunity causes retinal ganglion cell loss resulting in glaucomatous-like damage and according to the autoaggressive nature of some autoantibodies we found…

business.industryAutoantibodyGlaucomaAutoimmunityGlaucomaDiseasemedicine.diseasemedicine.disease_causeNeuroprotectionRetinaSensory SystemsAutoimmune DiseasesBiomarker (cell)AutoimmunityPathogenesisDisease Models AnimalOphthalmologyImmunologyProtective autoimmunitymedicineAnimalsHumanssense organsbusinessAutoantibodiesProgress in Retinal and Eye Research
researchProduct

Neuroprotection and autoimmunity in glaucoma

2012

In glaucoma, the elevated intraocular pressure cannot explain the disease in all patients. However, the pathogenesis of the disease is widely unknown. Biomarker research could be help to understand the disease process. Beside some genetic and proteomic biomarkers, immunoproteomics could play a significant role. Several studies could provide hints for an involvement of autoantibodies in the pathogenesis of the disease. The complex profiles of natural occurring autoantibodies were analyzed by Western Blotting and mass spectrometry based techniques combined with multivariate statistics and artificial neural networks. In several studies we could demonstrate consistent up- and down-regulations o…

business.industryAutoantibodyGlaucomaGeneral MedicineDiseasemedicine.diseasemedicine.disease_causeNeuroprotectionImmunoproteomicsAutoimmunityPathogenesisOphthalmologyImmunologyBiomarker (medicine)MedicinebusinessActa Ophthalmologica
researchProduct